Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Home/The Filing Wire/bioAffinity Technologies, Inc./ 8-K

Current Report · Items 7.01, 9.01 · 8-K

bioAffinity Technologies, Inc.

BIAFNASDAQEQUITYCurrent

Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. bioAffinity Technologies, Inc., a Delaware corporation, (the “Company”) has prepared presentation materials (the “Presentation Materials”) that management intends to use from time to time in presentations about the Company’s operations and performance, including at the H.C.…

Filed Sep 11, 2026Accepted Sep 11, 2026, 8:30 AM EDTCIK 1712762Accession 0001493152-26-042304
View company →Permanent SEC source ↗
Share

Company context

bioAffinity Technologies, Inc. addresses the need for non-invasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company’s first product, CyPath ® Lung, is a non-invasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. For more information, visit www.bioaffinitytech.com.

Current securities

BIAFNASDAQ · EQUITY · CurrentBIAFWNASDAQ · WARRANT · Current

Recent company filings

  1. Other EventsSep 22, 2026
  2. Other EventsSep 17, 2026
  3. Other EventsSep 9, 2026
  4. 424B3 filingSep 8, 2026
  5. EFFECT filingSep 4, 2026

Disclosure sections

Items 7.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. bioAffinity Technologies, Inc., a Delaware corporation, (the “Company”) has prepared presentation materials (the “Presentation Materials”) that management intends to use from time to time in presentations about the Company’s operations and performance, including at the H.C. Wainwright 28th Annual Global Investment Conference being held September 14, 2026, through September 16, 2026. The Presentation Materials are furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 7.01 and Exhibit 99.1 of this Current Report on Form 8-K are furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information in this Item 7.01 and Exhibit 99.1 of this Current Report on Form 8-K shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Current Report, regardless of any general incorporation language in any such filing.
Filed exhibits (1)